Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (April 2025)
29 slides from Sutro Biopharma's investor presentation, April 2025
Slide 1: Sutro Biopharma
Sutro Biopharma April 2025 NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
Slide 3: Strategic Restructuring to Accelerate Development of Next-Generation ADC Pipeline and Extend Cash Runway
Strategic Restructuring to Accelerate Development of Next-Generation ADC Pipeline and Significantly Extend Cash Runway Pipeline Restructuring and Optimized Clinical Priorities • Resources will be concentrated on advancing highly promising, novel ADCs for indications where there is greatest need • Th
Slide 4: Proprietary XpressCF Technology Platform: Enabling Precise Design of ADCs
Proprietary XpressCF® Technology Platform: Enabling Precise Design of ADCs with a Wide Range of Features Not Possible with Other Platforms With Our Next-Generation ADCs We Strive to Mitigate Toxicity Risk and Increase Dose to Improve Efficacy and Broaden the Addressable Patient Population Key Differ
Slide 5: Pipeline of Next-Generation ADCs
Pipeline of Next-Generation ADCs WORLDWIDE OR PHASE 3/ GEOGRAPHIC PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER WHOLLY-OWNED PROGRAMS STRO-004 Tissue Factor ADC Solid Tumors STRO-006 Integrin αvβ6 Solid Tumors STRO-00X Dual Payload ADC Solid Tumor
Slide 6: Well-Capitalized with Strong Business Development Track Record Validating Cell-Free Platform
6 Well-Capitalized with Strong Business Development Track Record Validating Cell-Free Platform in cash, cash equivalents Funding generated from our ~$317M (1)(3) & marketable securities (2) ~$980M collaborators ~$2 Billion Potential Future Milestones plus Royalties Phase 2/3 vaccines for invasive Pu
Slide 7: A Leader in Next-Gen ADCs
A Leader in Next-Gen ADCs Harnessing Complex Biology 7 NON CONFIDENTIAL
Slide 8: Wider Therapeutic Index Achieved with Sutro's Cell-Free ADC Platform
Wider Therapeutic Index Achieved with Sutro’s Cell-Free ADC Platform Key Sutro Technologies to Improve ADCs Outside the Tumor Linker & payload design MTD ADC Click chemistry Site specific conjugation MTD ADC Antibody engineering TI TI MED ADC Focused R&D Strategy – Make ADCs Better Inside the Tumor
Slide 9: Sutro's XpressCF Platform has Unique ADC Performance Capabilities Over Other Topo1 ADC Platforms
Sutro’s XpressCF® Platform has Unique ADC Performance Capabilities Over Other Topo1 ADC Platforms Beta-Glu ADC2/ iADC/ Site HT DAR>8 Fc Silent Bispecific Linker Dual LPs iSAC Specific Screening Abbvie AstraZeneca Daiichi Sankyo Dualitybio Genequantum Genmab Gilead Hansoh Hengrui Kelun Lilly Medilink
Slide 10: Sutro Cell-Free Approach Enables Industry-Leading ADC Exposure
1 0 Sutro Cell-Free Approach Enables Industry-Leading ADC Exposure Comparison of Exposure Levels in NHPs at Highest Non-Severely Toxic Dose (HNSTD) Levels in DAR Equivalents 6000 STRO-ADC Why does it matter? DAR4 Conjugated PL Exposure [h ug/mL] 5000 STRO-ADC STRO-004 • For ADCs, exposure drives eff
Slide 11: Differentiated Pipeline of ADCs, Each Designed for Improved Therapeutic Index
Differentiated Pipeline of ADCs, Each Designed for Improved Therapeutic Index and to Address Significant Unmet Need STRO-004 (TF) STRO-006 (ITGB6) Dual Payload Programs Opportunity for Sutro successfully identified Potential to overcome resistance by pan-tumor application with specific and selective
Slide 12: STRO-004
STRO-004 Exatecan ADC Targeting Tissue Factor 12 NON CONFIDENTIAL
Slide 13: STRO-004: Next-Generation Tissue Factor-Targeting Exatecan/Topo1 ADC
STRO-004: Next-Generation Tissue Factor-Targeting Exatecan/Topo1 ADC with Enhanced Therapeutic Potential Optimally Designed for Improved Clinical Benefits, Increased Tolerability Leads Enhanced Stability, Potency and Tumor Selectivity to Enhanced Drug Exposure • Exatecan payload: Clinically validate
Slide 14: STRO-004 DAR8 Exatecan Achieved Sustained Tumor Regressions in Xenograft Models
STRO-004 DAR8 Exatecan Achieved Sustained Tumor Regressions in Xenograft Models of NSCLC and HNSCC at Low Doses Lung (TF+++) Head and Neck (TF++) H1975 Growth Curves Detroit562 Growth Curves 1500 1500 (mm3)3) (mm33)) 1250 1250 Volume(mm volume(mm 1000 1000 Tumor Volume TumorVolume 750 750 500 500 Tu
Slide 15: STRO-004 Demonstrated Reduced Platform and On-target Toxicity
STRO-004 Demonstrated Reduced Platform and On-target Toxicity Due to Site Specific Conjugation and Beta Glu Linker-Payload Technology In Vitro STRO-004 Tolerability Profile vs. Approved aTF ADC Eye Inflammation Skin Toxicities Human Corneal Epithelial Cells Human Keratinocytes STRO-004 (DAR8-exateca
Slide 16: STRO-004: Well-Tolerated in NHP
STRO-004: Well-Tolerated in NHP up to 50 mg/kg Objective: HNSTD: 50 mg/kg HNSTD: 100 mg/kg Compare nonclinical safety of DAR8 and DAR4 TF exatecan-ADC DAR 8 DAR 4 10000 10000 Study: 1000 1000 Dosed twice, three weeks apart, Conc. [ug/mL] Conc. [ug/mL] 100 100 payload-matched doses 10 10 1 1 Findings
Slide 17: STRO-004 Shown Promising Anti-Tumor Activity In TF Positive PDX Models
STRO-004 has Shown Promising Anti-Tumor Activity In TF Positive PDX Models of HNSCC, NSCLC, and Esophageal Cancer > 50% of Tumors in PDX Models Respond to STRO-004 at Low Dose % Best response from baseline 100 % tumor volume chage 50 PD 0 PR -50 -100 STRO-004 (5 mg/kg) Approved aTF ADC (DAR4 MMAE) (
Slide 18: TF is Broadly Expressed Across Multiple Solid Tumor Indications
TF is Broadly Expressed Across Multiple Solid Tumor Indications with High Unmet Need, Presenting Opportunity for Pan-Tumor Targeting TF expression has been associated with poor disease prognosis and increased metastatic properties Tissue Factor-Expressing Cancers Estimate Of Newly-Diagnosed TF+ Pati
Slide 19: STRO-006 (Integrin αvβ6 / ITGB6)
STRO-006 (Integrin αvβ6 / ITGB6) Potential Best-in-Class Integrin-Beta 6 ADC 19 NON CONFIDENTIAL
Slide 20: Complex ITGB6 Biology Requires Advanced Protein Engineering Capabilities
Complex ITGB6 Biology Requires Advanced Protein Engineering Capabilities Integrin Family Integrin αvβ6 Conformations • ITGB6 belongs to integrin family of adhesion proteins, heterodimerizes with alpha-v (αvβ6) • Exists in multiple confirmations – makes it a challenging protein to target 20 NON CONFI
Slide 21: ITGB6 is Widely Expressed Across Multiple Solid Tumors
ITGB6 is Widely Expressed Across Multiple Solid Tumors Weighted Avg. Min Max 120% 100% 97% 100% 92% 98% 80% 84% 74% Expression % 77% 68% 68% 57% 60% 69% 64% 59% 43% 53% 37% 36% 40% 44% 35% 35% 35% 33% 30% 20% 26% 21% 18% 15% 12% 12% 0% Pancreatic Non-melanoma Cervical Esophageal Head and Neck Ovaria
Slide 22: Emerging Leader in Dual Payload ADCs
Emerging Leader in Dual Payload ADCs 22 NON CONFIDENTIAL
Slide 23: Dual Payload ADCs: Innovative Method for Delivering Targeted Combination Therapy
Dual Payload ADCs: Innovative Method for Delivering Targeted Combination Therapy ADC + Chemo ADC + ADC Dual Payload ADC Potential benefits of a dual payload ADCs for targeted combination therapy Safety Improved tolerability (Compared to small Through reduced systemic payload molecule combinations) G
Slide 24: Dual Payload ADC Displays Enhanced In Vivo Efficacy in Ovarian Cancer
Dual Payload ADC (Topo1i + anti-Tubulin) Displays Enhanced In Vivo Efficacy in Ovarian Cancer IGROV-1 - Tumor Growth IGROV-1 - Survival IGROV-1 - Time to Tumor Quadrupling Relative Tumor Volume (%) 1500 100 100 Percent Survival Percent survival 75 75 1000 50 50 500 25 25 0 0 0 0 20 40 60 80 100 0 20
Slide 25: iADC: Dual Payload ADC Combining Cytotoxin and Immune Stimulator
iADC: Dual Payload ADC Combining Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator Strategic Partnership with Astellas to Deliver New Treatment Options for Cold Tumors and Patients Unresponsive to Existing Cancer Immunotherapies Combining a cytotoxin and immune modulator gives potential t
Slide 26: Novel Mechanism of Action Differentiates iADC from Other Immunotherapies
Novel Mechanism of Action Differentiates iADC from Other Immunotherapies Sutro iADCs bridge innate and adaptive immunity to provide broad Sutro STING / PD-1 / CAR-T protection in a single molecule ISAC Vaccine iADC TLR PDL-1 Cells Molecule Targeted and Chemo Mixed ADC Ab Biologic Biologic homogeneou
Slide 27: Sutro's Proprietary Technology Enables Differentiated Dual Payload ADCs
Sutro's Proprietary Technology Enables the Development of Differentiated Dual Payload ADCs, Leveraging Unique Combinations of Validated Targets Dual Payload ADCs Have the Potential to Become Future Standard of Care Topo1 x Tubulin Topo1 x PARPi Topo1 x IO Selected Indications Selected Indications Se
Slide 28: Our Clinical and Corporate Priorities
Our Clinical and Corporate Priorities Sutro's Wholly-Owned Programs STRO-004 2H 2025: IND filing and first-in-human studies planned Exatecan ADC Targeting Tissue Factor 2026: Phase 1a/b dose escalation data expected 2027: Phase 1a/b dose expansion data expected (initial response data anticipated 1H
Slide 29: Sutro Team Comprised of Industry Leaders
Sutro Team Comprised of Industry Leaders Jane Chung, RPh Hans-Peter Gerber, PhD Barbara Leyman, PhD Chief Executive Officer Chief Scientific Officer Chief Business Officer Ed Albini, MBA David Pauling, JD, MA Venkatesh Srinivasan, PhD Chief Financial Officer Chief Administrative Officer and Chief Te